D. Margaret M. Seaman

Array ( [id] => 20505033 [patent_doc_number] => 12539295 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-03 [patent_title] => IRAK degraders and uses thereof [patent_app_type] => utility [patent_app_number] => 18/360277 [patent_app_country] => US [patent_app_date] => 2023-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 84628 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 693 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18360277 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18947107 [patent_doc_number] => 11890380 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-02-06 [patent_title] => Buccal formulation of avanafil with enhanced bioavailability and prolonged duration [patent_app_type] => utility [patent_app_number] => 18/191259 [patent_app_country] => US [patent_app_date] => 2023-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 10759 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18191259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18323080 [patent_doc_number] => 20230121208 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => Dispersible Tablet For Oral Administration [patent_app_type] => utility [patent_app_number] => 18/081875 [patent_app_country] => US [patent_app_date] => 2022-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18081875 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18254464 [patent_doc_number] => 20230081503 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-16 [patent_title] => USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION [patent_app_type] => utility [patent_app_number] => 17/990312 [patent_app_country] => US [patent_app_date] => 2022-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19715 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 91 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17990312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18368058 [patent_doc_number] => 11648205 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-05-16 [patent_title] => Buccal formulation of avanafil with enhanced bioavailability and prolonged duration [patent_app_type] => utility [patent_app_number] => 18/046700 [patent_app_country] => US [patent_app_date] => 2022-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 8 [patent_no_of_words] => 10842 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046700 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18142969 [patent_doc_number] => 20230016814 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => MARKERS FOR PHARMACEUTICALS [patent_app_type] => utility [patent_app_number] => 17/947780 [patent_app_country] => US [patent_app_date] => 2022-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6818 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17947780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17913118 [patent_doc_number] => 20220315513 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => 11-HALO-1,1-DIALKOXY-7-UNDECENE COMPOUND AND PROCESSES FOR PREPARING A 11,11-DIALKOXY-4-UNDECENYLTRIARYLPHOSPHONIUM HALIDE COMPOUND, A TRIENAL COMPOUND, AND A DIENAL COMPOUND [patent_app_type] => utility [patent_app_number] => 17/698022 [patent_app_country] => US [patent_app_date] => 2022-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17698022 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17546665 [patent_doc_number] => 20220118006 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => MAGNESIUM/LITHIUM PREPARATIONS FOR NEUROPROTECTION AND NEUROTROPHIC BENEFITS [patent_app_type] => utility [patent_app_number] => 17/567643 [patent_app_country] => US [patent_app_date] => 2022-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4035 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17567643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18324224 [patent_doc_number] => 20230122352 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => METHOD OF TREATING ORAL PAIN WITH AN EFFERVESCING COMPOSITION [patent_app_type] => utility [patent_app_number] => 17/451241 [patent_app_country] => US [patent_app_date] => 2021-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 794 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17451241 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17383757 [patent_doc_number] => 20220031609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => ORGANIC COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/501173 [patent_app_country] => US [patent_app_date] => 2021-10-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5960 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17501173 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17881027 [patent_doc_number] => 20220296504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-22 [patent_title] => INTRANASAL DELIVERY OF LEVODOPA POWDER BY PRECISION OLFACTORY DEVICE [patent_app_type] => utility [patent_app_number] => 17/498381 [patent_app_country] => US [patent_app_date] => 2021-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14240 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17498381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17383811 [patent_doc_number] => 20220031663 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => USE OF SUBLINGUAL DEXMEDETOMIDINE FOR THE TREATMENT OF AGITATION [patent_app_type] => utility [patent_app_number] => 17/496470 [patent_app_country] => US [patent_app_date] => 2021-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19797 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17496470 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18496054 [patent_doc_number] => 20230218589 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-13 [patent_title] => COMPOUND FOR PREVENTION OR TREATMENT OF A SKIN CANCER OR SKIN PRECANCER [patent_app_type] => utility [patent_app_number] => 18/009642 [patent_app_country] => US [patent_app_date] => 2021-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16151 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18009642 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17124321 [patent_doc_number] => 20210299089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/332800 [patent_app_country] => US [patent_app_date] => 2021-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25359 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17005301 [patent_doc_number] => 20210236462 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => SUSTAINED RELEASE LINGUAL THIOCTIC ACID DELIVERY SYSTEMS [patent_app_type] => utility [patent_app_number] => 17/236972 [patent_app_country] => US [patent_app_date] => 2021-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16461 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17236972 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18716465 [patent_doc_number] => 11793786 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-10-24 [patent_title] => Administration of benzodiazepine compositions [patent_app_type] => utility [patent_app_number] => 17/228514 [patent_app_country] => US [patent_app_date] => 2021-04-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25350 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17228514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16883611 [patent_doc_number] => 20210169806 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => AGENTS FOR ORAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 17/170998 [patent_app_country] => US [patent_app_date] => 2021-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19975 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17170998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16976136 [patent_doc_number] => 20210220373 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => ORALLY DISINTEGRATING PHARMACUTICAL COMPOSITION COMPRISING NEFOPAM AND PROCESS FOR PREPARING THE SAME [patent_app_type] => utility [patent_app_number] => 17/149127 [patent_app_country] => US [patent_app_date] => 2021-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3343 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17149127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18075836 [patent_doc_number] => 20220401448 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => Pharmaceutical Compositions Comprising an Inhibitor of a Histon-deacetylase (HDACi) and an Agonist of Toll-like-receptor 7 and/or 8 (TLR7 and/or TLR8) and Their Use in the Treatment of Cancer [patent_app_type] => utility [patent_app_number] => 17/777556 [patent_app_country] => US [patent_app_date] => 2020-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16670 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17777556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140076 [patent_doc_number] => 20210308087 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => TREATMENT AND PREVENTION OF BONE LOSS USING RESOLVINS [patent_app_type] => utility [patent_app_number] => 17/097465 [patent_app_country] => US [patent_app_date] => 2020-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10870 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17097465 [rel_patent_id] =>[rel_patent_doc_number] =>)